Uy Ear
Stock Analyst at Mizuho
(4.18)
# 410
Out of 5,127 analysts
77
Total ratings
48.94%
Success rate
18.41%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $137.65 | +27.13% | 11 | Dec 12, 2025 | |
| QURE uniQure | Maintains: Outperform | $60 → $33 | $24.71 | +33.55% | 6 | Dec 9, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $4.45 | +326.97% | 4 | Dec 2, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $24 → $29 | $22.70 | +27.75% | 15 | Dec 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $32 → $37 | $26.88 | +37.65% | 15 | Nov 28, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $1 → $10 | $4.02 | +148.76% | 2 | Nov 19, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $19 → $26 | $18.33 | +41.84% | 9 | Nov 5, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $34.72 | +29.61% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $37.68 | +48.62% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $21.05 | +303.80% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $6.47 | +518.24% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $238.35 | -83.22% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.60 | +284.62% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.42 | +111.27% | 2 | Mar 1, 2023 |
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $137.65
Upside: +27.13%
uniQure
Dec 9, 2025
Maintains: Outperform
Price Target: $60 → $33
Current: $24.71
Upside: +33.55%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $4.45
Upside: +326.97%
ACADIA Pharmaceuticals
Dec 2, 2025
Maintains: Neutral
Price Target: $24 → $29
Current: $22.70
Upside: +27.75%
Arcutis Biotherapeutics
Nov 28, 2025
Maintains: Outperform
Price Target: $32 → $37
Current: $26.88
Upside: +37.65%
Relmada Therapeutics
Nov 19, 2025
Upgrades: Outperform
Price Target: $1 → $10
Current: $4.02
Upside: +148.76%
Sarepta Therapeutics
Nov 5, 2025
Upgrades: Outperform
Price Target: $19 → $26
Current: $18.33
Upside: +41.84%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $34.72
Upside: +29.61%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $37.68
Upside: +48.62%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $21.05
Upside: +303.80%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $6.47
Upside: +518.24%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $238.35
Upside: -83.22%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.60
Upside: +284.62%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.42
Upside: +111.27%